Muzinich & Company Has Lifted Its Blackrock Capital Invest (BKCC) Stake; Crispr Therapeutics AG (CRSP) Shorts Up By 60.74%

December 12, 2017 - By Kurt Siggers

Crispr Therapeutics AG (NASDAQ:CRSP) had an increase of 60.74% in short interest. CRSP’s SI was 998,700 shares in December as released by FINRA. Its up 60.74% from 621,300 shares previously. With 211,000 avg volume, 5 days are for Crispr Therapeutics AG (NASDAQ:CRSP)’s short sellers to cover CRSP’s short positions. The SI to Crispr Therapeutics AG’s float is 12.25%. The stock decreased 2.82% or $0.52 during the last trading session, reaching $17.89. About 508,145 shares traded or 103.37% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has 0.00% since December 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Muzinich & Company increased Blackrock Capital Invest (BKCC) stake by 17.82% reported in 2017Q2 SEC filing. Muzinich & Company acquired 403,683 shares as Blackrock Capital Invest (BKCC)’s stock declined 2.45%. The Muzinich & Company holds 2.67 million shares with $19.99 million value, up from 2.27M last quarter. Blackrock Capital Invest now has $477.08M valuation. The stock increased 0.15% or $0.01 during the last trading session, reaching $6.52. About 613,003 shares traded or 92.39% up from the average. BlackRock Capital Investment Corporation (NASDAQ:BKCC) has risen 2.85% since December 12, 2016 and is uptrending. It has underperformed by 13.85% the S&P500.

Among 6 analysts covering BlackRock Kelso Capital (NASDAQ:BKCC), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. BlackRock Kelso Capital had 10 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of BlackRock Capital Investment Corporation (NASDAQ:BKCC) earned “Buy” rating by Cantor Fitzgerald on Wednesday, August 19. The stock of BlackRock Capital Investment Corporation (NASDAQ:BKCC) earned “Market Perform” rating by Keefe Bruyette & Woods on Friday, February 19. The firm has “Buy” rating given on Wednesday, September 30 by DA Davidson. On Thursday, October 5 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. DA Davidson downgraded BlackRock Capital Investment Corporation (NASDAQ:BKCC) rating on Thursday, April 28. DA Davidson has “Neutral” rating and $9 target. Citigroup maintained BlackRock Capital Investment Corporation (NASDAQ:BKCC) rating on Tuesday, June 14. Citigroup has “Neutral” rating and $8 target. The company was maintained on Thursday, November 9 by Keefe Bruyette & Woods. The stock of BlackRock Capital Investment Corporation (NASDAQ:BKCC) has “Hold” rating given on Monday, August 14 by Keefe Bruyette & Woods. As per Wednesday, November 1, the company rating was maintained by JP Morgan.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $733.84 million. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

Among 5 analysts covering CRISPR Therapeutics (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. CRISPR Therapeutics had 5 analyst reports since November 14, 2016 according to SRatingsIntel. The stock has “Overweight” rating by Piper Jaffray on Monday, November 14. The rating was initiated by Guggenheim on Monday, November 14 with “Buy”. The firm has “Neutral” rating given on Tuesday, November 15 by Citigroup. The firm has “Overweight” rating by Barclays Capital given on Monday, November 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.